… In our trial, the use of convalescent plasma therapy in addition to standard treatment in patients
with severe pneumonia due to Covid-19 … We believe the use of convalescent plasma as a …

… Convalescent plasma has antiviral activity and early … reducing COVID-19 severity. We
investigated the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19 …

… Early in a pandemic, such as the ongoing outbreak of the coronavirus disease-19 (COVID-19)
caused by severe acute … A randomized trial from Spain (n = 350) reported a benefit of …

… randomized clinical trial enrolled (1:1 ratio) hospitalized patients with COVID-19 pneumonia
… Hospitalized adults with COVID-19 pneumonia and a partial pressure of oxygen–to–fraction …

… COVID-19 convalescent plasma (CCP) has been widely used but results from randomized
trials … assess the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia. …

… Our trial result was also in agreement with a randomized trial conducted in India in 464 …
randomized trial by Simonov et al. that studied CP in COVID-19 with severe pneumonia …

… Available data suggest that approximately 10%–25% of patients with SARS-CoV-2
infection develop severe COVID-19 characterized primarily by pneumonia and in a subset, …

… in prior pandemics 3 -5 and randomized trials for diphtheria 6 ,7 and Argentine hemorrhagic
… criteria: chronic pulmonary or heart conditions, hypertension, chronic kidney disease, body …

… Based on previous experience in other viral infections 2 , the use of convalescent plasma …
with acute COVID-19 (refs. ). Early in the pandemic, several small randomized trials found no …

… for neurologic reasons, not pneumonia, a prerequisite for inclusion in this study (Figure 1). …
Our results are in agreement with those obtained in another randomized study, in which 464 …